| 0.8731 -0.008 (-0.89%) | 10-04 10:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.1 | 1-year : | 1.28 |
| Resists | First : | 0.94 | Second : | 1.1 |
| Pivot price | 0.76 |
|||
| Supports | First : | 0.78 | Second : | 0.68 |
| MAs | MA(5) : | 0.84 |
MA(20) : | 0.75 |
| MA(100) : | 0.88  |
MA(250) : | 0.98 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 73.8 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 1.95 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KPTI ] has closed below upper band by 6.9%. Bollinger Bands are 28.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.93 | 0.93 - 0.94 |
| Low: | 0.83 - 0.83 | 0.83 - 0.84 |
| Close: | 0.87 - 0.88 | 0.88 - 0.89 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Tue, 01 Oct 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Tue, 01 Oct 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Tue, 01 Oct 2024
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S - Simply Wall St
Thu, 05 Sep 2024
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround - Yahoo Finance
Tue, 06 Aug 2024
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Wed, 24 Jul 2024
Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 125 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 56.7 (%) |
| Shares Short | 17,930 (K) |
| Shares Short P.Month | 18,260 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.06 |
| Profit Margin | -61.8 % |
| Operating Margin | -65.8 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.16 |
| EBITDA (p.s.) | -1.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -130 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | -0.84 |
| Price to Sales | 0.75 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|